Operator

Good afternoon, ladies and gentlemen, and welcome to the Precigen First Quarter 2026 Financial Results and Business Update Conference Call.

[Operator Instructions] This call is being recorded on Wednesday, May 13, 2026.

And I would now like to turn the conference over to Mr. Steven Harasym. Please go ahead, sir.

Steven Harasym
VP & Head of Investor Relations

Thank you, operator, and thank you for all those joining us today for our Q1 2026 update call.

Joining me today are Dr. Helen Sabzevari, our President and CEO; Phil Tennant, our Chief Commercial Officer; Harry Thomasian, our CFO; and Raul Shah, our COO.

Before we begin our prepared remarks, I remind everyone that we will be making certain forward-looking statements during this call. These statements are based on our current expectations and beliefs. We encourage you to review the slide in this presentation as well as our SEC filings, which include risks and uncertainties that could cause actual results to differ materially from today's forward-looking statements.

With that, I will now turn the call over to Dr. Sabzevari.

Helen Sabzevari
President, CEO & Director

Thank you, Steve, and thank you to all those joining us for our Q1 update call.

The approval of PAPZIMEOS in August of 2025 has brought a novel first-line standard of care treatment for adults with RRP. In nine short months, we have witnessed tremendous progress with the first commercial therapeutic launch in